Nuvation Bio (NUVB)
NYSE:NUVB
NUVB Stock Chart & Stats
$4.70
-$0.19(-5.85%)
At close: 4:00 PM EST
$4.70
-$0.19(-5.85%)
Day’s Range― - ―
52-Week Range$1.57 - $9.75
Previous CloseN/A
Volume977.37K
Average Volume (3M)4.45M
Market Cap
$1.60B
Enterprise Value$1.48B
Total Cash (Recent Filing)$529.21M
Total Debt (Recent Filing)$10.15M
Price to Earnings (P/E)―
Beta1.80
Next Earnings
May 19, 2026EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding346,597,300
10 Day Avg. Volume2,811,174
30 Day Avg. Volume4,448,896
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)10.01
Price to Sales (P/S)48.65
P/FCF Ratio-17.61
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue23.45
Enterprise Value/Gross Profit27.09
Enterprise Value/Ebitda-7.53
Forecast
1Y Price Target
$13.17Price Target Upside180.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.47
Revenue Forecast (FY)$193.36M
Bulls Say, Bears Say
Bulls Say
Clinical Development StrategyDurable Phase 2 responses for safusidenib and management's plan to pursue an accelerated regulatory pathway with a focused registration trial create prospects for quicker approval and meaningful data-driven value inflection.
Commercial UptakeIbtrozi's rapid market penetration across multiple therapy lines and an exclusive ex-U.S. licensing deal with a major partner indicate stronger commercial traction and recurring revenue potential.
Regulatory ApprovalEMA validation of the marketing application for taletrectinib, supported by pooled pivotal trial data and favorable rapporteur feedback, advances the filing toward potential EU approval and associated milestone payments.
Bears Say
Clinical RiskNegative proof-of-concept results for any pipeline candidate could materially weaken the company's outlook by undermining approval prospects and investor confidence.
Financial And Governance RiskPotential dilution from future financing needs, along with conflicts of interest in some research coverage, could undermine investor confidence and cloud valuation clarity.
Product Adoption RiskHigh treatment discontinuation linked to patients starting Ibtrozi in later therapy lines, combined with intense competition, could suppress sales momentum and slow broader adoption.
Nuvation Bio News
NUVB FAQ
What was Nuvation Bio’s price range in the past 12 months?
Nuvation Bio lowest stock price was $1.57 and its highest was $9.75 in the past 12 months.
What is Nuvation Bio’s market cap?
Nuvation Bio’s market cap is $1.60B.
When is Nuvation Bio’s upcoming earnings report date?
Nuvation Bio’s upcoming earnings report date is May 19, 2026 which is in 35 days.
How were Nuvation Bio’s earnings last quarter?
Nuvation Bio released its earnings results on Mar 02, 2026. The company reported -$0.11 earnings per share for the quarter, missing the consensus estimate of -$0.089 by -$0.021.
Is Nuvation Bio overvalued?
According to Wall Street analysts Nuvation Bio’s price is currently Undervalued.
Does Nuvation Bio pay dividends?
Nuvation Bio does not currently pay dividends.
What is Nuvation Bio’s EPS estimate?
Nuvation Bio’s EPS estimate is <0.01.
How many shares outstanding does Nuvation Bio have?
Nuvation Bio has 346,597,300 shares outstanding.
What happened to Nuvation Bio’s price movement after its last earnings report?
Nuvation Bio reported an EPS of -$0.11 in its last earnings report, missing expectations of -$0.089. Following the earnings report the stock price went down -25.342%.
Which hedge fund is a major shareholder of Nuvation Bio?
Currently, no hedge funds are holding shares in NUVB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nuvation Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.17 (180.21% Upside)
$13.17 (180.21% Upside)
Blogger Sentiment
Bullish
NUVB Sentiment 75%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 3.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.3%
Last 30 Days ▲ 0.5%
Last 30 Days ▲ 0.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
162.85%
12-Months-Change
Fundamentals
Return on Equity
-57.48%
Trailing 12-Months
Asset Growth
10.02%
Trailing 12-Months
Company Description
Nuvation Bio
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.
NUVB Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights a number of strong clinical and commercial progress points — U.S. approval of IBTROZI, rapid new patient starts (~6x faster vs. prior launches), compelling durability data (median DOR 50 months in TKI‑naive), broad payer access, strong cash position ($529.2M), and advancing pipeline programs (safusidenib Phase III initiation and a non‑pivotal cohort with potential accelerated pathway). Offsetting these positives are near‑term commercial headwinds: a mismatch between new patient starts and net product revenue due to an early mix skewed toward later‑line patients who discontinue quickly, rising gross‑to‑net (~25%), high operating costs (R&D $115.1M; SG&A $151.6M), a discontinued DDC candidate, and long timelines for pivotal readouts (safusidenib SIGMA readout expected 2029). Overall, the call projects long‑term upside driven by clinical differentiation and international partnerships while acknowledging short‑term revenue and execution uncertainties.View all NUVB earnings summariesNUVB Stock 12 Month Forecast
Average Price Target
$13.17
▲(180.21% Upside)
Technical Analysis
Nektar Therapeutics
―
Precigen
―
Wave Life Sciences
―
Enliven Therapeutics
―
Praxis Precision Medicines
―
Ownership Overview
24.92% Insiders
16.53% Mutual Funds
19.53% Other Institutional Investors
29.72% Public Companies and Individual Investors